GDC-0077, also known as inavolisib, is a potential therapeutic agent undergoing clinical trials for the treatment of advanced solid tumors. It belongs to the class of drugs known as phosphoinositide 3-kinase (PI3K) inhibitors, which are increasingly being recognized for their potential in the treatment of cancer.
Chemical Name: The chemical name of GDC-0077 is (S)-2-(1-((9H-purin-6-yl)amino)ethyl)-6-fluoro-3-(3-methoxyphenyl)-4-oxoquinoline-5-carboxamide.
Molecular Formula: The molecular formula of GDC-0077 is C25H19FN6O3.
Formula Weight: The molecular weight of GDC-0077 is 480.46 g/mol.
CAS No: The CAS number of GDC-0077 is 2060571-02-8.
Top Ten Keywords from Google and Synonyms:
Synonyms: GDC-0077 is also known by its brand name, which is "Inavolisib." Other synonyms include PI3K inhibitor GDC-0077, and (S)-2-((6-(9H-Purin-6-ylamino)hexyl)amino)-6-fluoro-3-(3-methoxyphenyl)quinolin-4(1H)-one.
Health Benefits of GDC-0077: GDC-0077 is still under development; hence, there are no established health benefits at present. However, preclinical studies have shown that it has significant potential in inhibiting tumor growth and proliferation in various cancer types, including breast, ovarian, gastric, and endometrial cancers.
Potential Effects: Preclinical studies have demonstrated that GDC-0077 can inhibit the activity of PI3K, a protein kinase that plays a crucial role in cell growth, proliferation, and survival. By inhibiting PI3K, GDC-0077 can prevent the activation of downstream signaling pathways involved in tumorigenesis, thus hindering tumor growth and progression. Additionally, it has shown promising results in combination with other targeted therapies, such as anti-HER2 agents, in preclinical models of breast cancer.
Product Mechanism: GDC-0077 is a selective inhibitor of the delta isoform of PI3K, a subtype of PI3K that is commonly mutated in various cancers. It selectively targets cancer cells with activated PI3K and inhibits its activity, thus stopping the downstream signaling pathways that promote cell growth and proliferation. This mechanism of action makes GDC-0077 a promising drug candidate for the treatment of PI3K pathway-activated cancers.
Safety: GDC-0077 is still under investigation, and its safety profile is yet to be fully established. However, early-phase clinical trials have reported manageable toxicities, including nausea, vomiting, fatigue, and diarrhea. As with any investigational drug, it is vital to carry out rigorous safety assessments before it becomes available for widespread use.
Side Effects: Common side effects reported in early-phase clinical trials include:
Dosing Information: GDC-0077 is currently being evaluated in Phase I/II clinical trials to determine the optimal dose and schedule for administration. The recommended dose and dosing regimen will be determined based on the outcome of these trials.
Conclusion: GDC-0077, also known as Inavolisib, is an investigational drug with promising potential as a therapeutic agent for the treatment of advanced solid tumors. It selectively targets the delta isoform of PI3K, inhibiting its activity and preventing downstream signaling pathways that promote tumor growth and proliferation. Early-phase clinical trials have reported manageable toxicities, and ongoing clinical trials hope to determine its safety and efficacy further. If proven effective, GDC-0077 could offer a new option for patients with PI3K pathway-activated cancers. However, more extensive clinical trials are needed to establish its safety profile and determine the most effective dosing regimen.
